The DUTCH test provides a detailed picture of sex hormone production and metabolism, and how estrogen is being broken down and cleared from the body.

Not all estrogen metabolites carry the same risk profile. The ratio of 2-hydroxyestrone to 16α-hydroxyestrone has been studied in relation to breast cancer risk, and the methylation pathway producing 2-methoxyestrone is considered protective. Knowing which pathways are dominant (and whether they're working efficiently) is genuinely useful clinical information at every stage of breast cancer care.

For women focused on risk reduction, the DUTCH provides a baseline picture of estrogen metabolism that can be actively improved through diet, lifestyle, and targeted support.

For women in active treatment on aromatase inhibitors or other hormone-blocking therapies, it shows how well estrogen is being suppressed and whether detoxification pathways are functioning optimally alongside treatment.

For women post-treatment, it supports ongoing monitoring of the hormonal environment - one of the most relevant factors in long-term recurrence risk reduction.

The OAT measures metabolic byproducts in urine that reflect mitochondrial function, gut microbial activity, neurotransmitter metabolism, and nutrient cofactor status. It's particularly useful for unpacking cancer-related fatigue, cognitive symptoms, and the metabolic toll of treatment.

Mitochondrial dysfunction is increasingly recognized as both a contributor to cancer biology and a consequence of certain chemotherapy agents. The OAT offers a functional window into this that standard panels don't provide.

The gut microbiome influences immune regulation, inflammatory signaling, estrogen metabolism, and response to cancer treatment itself.

A landmark 2018 study found that gut microbiome composition predicted response to PD-1 checkpoint inhibitor immunotherapy, with patients carrying higher microbial diversity showing significantly better outcomes.

The estrobolome (the collection of gut bacteria responsible for estrogen recycling) is directly relevant in hormone-sensitive cancers. Dysbiosis in this system can increase circulating estrogen levels independent of ovarian production.

Microbiome testing allows us to assess diversity, identify dysbiosis patterns, and target the protocol accordingly.

HTMA measures mineral levels and heavy metal burden accumulated in hair tissue over approximately three months, providing a longer-term picture than serum testing. It is most useful for assessing mineral ratios and identifying heavy metal accumulation that may be contributing to immune or metabolic dysfunction.

Heavy metal burden is particularly relevant in a cancer context. Certain chemotherapy agents, platinum-based treatments especially are associated with increased heavy metal accumulation in tissue post-treatment.

Elevated heavy metal concentrations are also independently associated with increased cancer risk, making assessment relevant not only after treatment but as part of proactive cancer risk reduction.

I use HTMA as one data point within a broader picture, and I'm transparent with patients about where its evidence base is stronger and where it requires careful interpretation.

This isn't a separate blood draw, it's a different way of reading the results you likely already have. Using optimal ranges rather than pathological cutoffs, and tracking markers across time rather than in isolation, functional blood chemistry interpretation can identify patterns that standard reporting misses entirely.

I review full blood counts, metabolic panels, thyroid function, inflammatory markers, iron studies, and key nutrients. I also analyze the picture they form together, not each result independently.

Genetic testing in an integrative oncology context is not just about identifying mutations (your oncologist manages that conversation). It's about understanding how your genes impact your nutrient levels, detoxification, and inflammatory signaling, and using that information to make smarter decisions about diet and supplementation.

Variants in genes like MTHFR, COMT, and VDR influence folate metabolism, estrogen clearance, and vitamin D receptor function respectively - all relevant in cancer care.

Importantly, genetic variants are not fixed outcomes. This is where epigenetics becomes clinically useful: gene expression is regulated by environmental signals (including diet, stress, toxic exposures, and lifestyle factors) which means the same variant can behave very differently depending on our nutrition and lifestyle choices.